Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: A prospective study in a clinically-relevant spectrum of patients

European Journal of Epidemiology

Volumn 26, Issue 3, 2011, Pages 229-236

  Parker, Lucy A ^a,c   Porta, Miquel ^b,d,e   Lumbreras, Blanca ^a,c   López, Tomàs ^c,d   Guarner, Luisa ^e,f   Hernández Aguado, Ildefonso ^a,c   Carrato, Alfredo ^g   Corominas, Josep M ^d,e   Rifà, Juli ^h   Fernandez, Esteve ^d,i   Alguacil, Joan ^d,j   Malats, Núria ^d,k   Real, Francisco X ^d,k,l  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

^j UNIVERSITY OF HUELVA   (Spain)

^k Centro Nacional de Investigaciones Oncológicas   (Spain)

^l UNIVERSITAT POMPEU FABRA   (Spain)

more..

Author keywords

Diagnosis analysis; Diagnosis diagnostic use; Diagnosis methods; Epidemiology diagnosis; Genes, ras; KRAS oncogene; Oncogene protein p21 ras; Pancreatic neoplasms diagnosis; Research methods

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CHRONIC PANCREATITIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; GENE MUTATION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PANCREAS CANCER; PANCREAS CYST; PATIENT IDENTIFICATION; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; VALIDITY;

AGED; AGED, 80 AND OVER; FEMALE; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 79955579178     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-011-9547-8     Document Type: Article

References (49)

1. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7: 163-72.
2. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605-17.
3. Takhar AS, Palaniappan P, Dhingsa R, Lobo DN. Recent developments in diagnosis of pancreatic cancer. BMJ. 2004;329: 668-73. (Pubitemid 39279289)
4. Porta M, Fabregat X, Malats N, Guarner L, Carrato A, de Miguel A, et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol. 2005;7:189-97.
5. Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, et al. Tumor markers in pancreatic cancer: an European group on tumor markers (EGTM) status report. Ann Oncol. 2010;21:441-7.
6. Freelove R, Walling A. Pancreatic cancer: diagnosis and management. Am Fam Physician. 2006;73:485-92. (Pubitemid 43211735)
7. Beger HG, Matsuno S, Cameron JL. Diseases of the pancreas: current surgical therapy. Berlin: Springer; 2008.
8. von Hoff DD, Evans DB, Hruban RH, editors. Pancreatic cancer. Boston: Jones and Bartlett; 2005.
9. Howard JM, Idezuki Y, Ihse I, Prinz RA, editors. Surgical diseases of the pancreas. 3rd ed. Baltimore: Williams and Wilkins; 1998.
10. Beger HG, Warshaw AL, Büchler MW, Carr-Locke DL, Neoptolemos JP, Russell C, Sarr MG, editors. The pancreas. Vol. 2. Oxford: Blackwell; 1998.
11. Abraham SC, Wilentz RE, Yeo CJ, Sohn TA, Cameron JL, Boitnott JK, et al. Pancreaticoduodenectomy (Whipple resections) in patients without malignancy: are they all 'chronic pancreatitis'? Am J Surg Pathol. 2003;27:110-20. (Pubitemid 36014904)
12. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1998;53:549-54.
13. Tada M, Omata M, Ohto M. Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma. Gastroenterology. 1991;100:233-8.
14. Parker LA, Lumbreras B, Hernández-Aguado I, Porta M. How useful is it clinically to analyse the K-ras mutational status for the diagnosis of exocrine pancreatic cancer? A systematic review and meta-analysis. Eur J Clin Invest. 2011 (in press).
15. Marchese R, Muleti A, Pasqualetti P, Bucci B, Stigliano A, Brunetti E, et al. Low correspondance between K-ras mutations in pancreatic câncer tissue and detection of K-ras mutations in circulating DNA. Pancreas. 2006;32:171-7.
16. Wenger FA, Zieren J, Peter FJ, Jacobi CA, Müller JM. K-ras mutations in tissue and stool samples from patients with pancreatic cancer and chronic pancreatitis. Langenbecks Arch Surg. 1999;384:181-6. (Pubitemid 29227310)
17. Trümper L, Menges M, Daus H, Köhler D, Reinhard JO, Sackmann M, et al. Low sensitivity of the ki-ras polymerase chain reaction for diagnosing pancreatic cancer from pancreatic juice and bile: a multicenter prospective trial. J Clin Oncol. 2002;20:4331-7. (Pubitemid 35266294)
18. Liu TH, Wang ZY, Cui QC. Significance of the detection of Ki-ras codon 12 mutation in the diagnosis of pancreatic carcinoma. Int J Surgical Path. 1995;3:93-100.
19. Van Laethem JL, Vertongen P, Deviere J, Van Rampelbergh J, Rickaert F, Cremer M, Robberecht P. Detection of c-Ki-ras gene codon 12 mutations from pancreatic duct brushings in the diagnosis of pancreatic tumours. Gut. 1995;36:781-7.
20. Zheng M, Liu LX, Zhu AL, Qi SY, Jiang HC, Xiao ZY. K-ras gene mutation in the diagnosis of ultrasound guided fine-needle biopsy of pancreatic masses. World J Gastroenterol. 2003;9:188-91. (Pubitemid 36131307)
21. Mora J, Puig P, Boadas J, Urgell E, Montserrat E, Lerma E, et al. K-ras gene mutations in the diagnosis of fine-needle aspirates of pancreatic masses: prospective study using two techniques with different detection limits. Clin Chem. 1998;44:2243-8. (Pubitemid 28511744)
22. Shibata D, Almoguera C, Forrester K, Dunitz J, Martin SE, Cosgrove MM, et al. Detection of c-K-ras mutations in fine needle aspirates from human pancreatic adenocarcinomas. Cancer Res. 1990;50:1279-83. (Pubitemid 20084023)
23. Villanueva A, Reyes G, Cuatrecasas M, Martínez A, Erill N, Lerma E, et al. Diagnostic utility of K-ras mutations in fine-needle aspirates of pancreatic masses. Gastroenterology. 1996;110:1587-94. (Pubitemid 26134093)
24. Pugliese V, Pujic N, Saccomanno S, Gatteschi B, Pera C, Aste H, Ferrara GB, Nicolò G. Pancreatic intraductal sampling during ERCP in patients with chronic pancreatitis and pancreatic cancer: cytologic studies and k-ras-2 codon 12 molecular analysis in 47 cases. Gastrointest Endosc. 2001;54:595-9. (Pubitemid 33666031)
25. Van Laethem JL, Bourgeois V, Parma J, Delhaye M, Cochaux P, Velu T, et al. Relative contribution of Ki-ras gene analysis and brush cytology during ERCP for the diagnosis of biliary and pancreatic diseases. Gastrointest Endosc. 1998;47:479-85. (Pubitemid 28287566)
26. Parker LA, Gómez Saez N, Lumbreras B, Porta M, Hernández-Aguado I. Methodological deficits in diagnostic research using '-omics' technologies: Evaluation of the QUADOMICS tool and quality of recently published studies. PLoS One. 2010;5(7): e11419.
27. Fletcher RH, Fletcher SW. Clinical epidemiology. The essentials. 4th ed. Philadelphia: Lippincott, Williams and Wilkins; 2005.
28. Haynes RB, Sackett DL, Guyatt GH, Tugwell P. Clinical epidemiology. How to do clinical practice research. 3rd ed. Philadelphia: Lippincott, Williams and Wilkins; 2005.
29. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93:1054-61. (Pubitemid 32717537)
30. Porta M, ed. A dictionary of epidemiology. 5th ed. New York: Oxford University Press; 2008. p. 66, 69, 191, 201, 227, 233-6, 255, 258.
31. Porta M, Malats N, Jariod M, Grimalt JO, Rifà J, Carrato A, et al. Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. Lancet. 1999;354: 2125-9. (Pubitemid 30008897)
32. Soler M, Malats N, Porta M, Fernandez E, Guarner L, Maguire A, et al. Medical conditions in patients with pancreatic and biliary diseases: validity and agreement between data from questionnaires and medical records. Dig Dis Sci. 1999;44:2469-77. (Pubitemid 30027363)
33. Porta M, Costafreda S, Malats N, Guarner L, Soler M, Gubern JM, et al. Validity of the hospital discharge diagnosis in epidemiologic studies of biliopancreatic pathology. Eur J Epidemiol. 2000;16:533-41.
34. Porta M, Malats N, Alguacil J, Ruiz L, Jariod M, Carrato A, et al. Coffee, pancreatic cancer, and K-ras mutations: updating the research agenda. J Epidemiol Community Health. 2000;54: 656-9. (Pubitemid 30639396)
35. Real FX, Malats N, Lesca G, Porta M, Chopin S, Lenoir GM, et al. Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreas cancer. Gut. 2002;50:653-7. (Pubitemid 34407492)
36. Alguacil J, Porta M, Malats N, Kauppinen T, Kogevinas M, Benavides FG, et al. Occupational exposure to organic solvents and K-ras mutations in exocrine pancreatic cancer. Carcinogenesis. 2002;23:101-6. (Pubitemid 34213558)
37. Morales E, Porta M, Vioque J, López T, Mendez MA, Pumarega JA, et al. Food and nutrient intakes and K-ras mutations in exocrine pancreatic cancer. J Epidemiol Community Health. 2007;61:641-9. (Pubitemid 46998899)
38. Crous-Bou M, De Vivo I, Porta M, Pumarega JA, López T, Alguacil J, et al. CYP1B1 polymorphisms and K-ras mutations in patients with pancreatic ductal adenocarcinoma. Dig Dis Sci. 2008;53:1417-21.
39. Crous-Bou M, Porta M, López T, Jariod M, Malats N, Alguacil J, et al. Lifetime history of tobacco consumption and K-ras mutations in exocrine pancreatic cancer. Pancreas. 2007;35:135-41. (Pubitemid 47075567)
40. Crous-Bou M, Porta M, López T, Jariod M, Malats N, Morales E, et al. Lifetime history of alcohol consumption and K-ras mutations in pancreatic ductal adenocarcinoma. Environ Mol Mutagen. 2009;50:421-30.
41. Crous-Bou M, Porta M, Morales E, López T, Carrato A, Puigdomè nech E, et al. Past medical conditions and K-ras mutations in pancreatic ductal adenocarcinoma: a hypothesis-generating study. Cancer Causes Control. 2009;20:591-9.
42. Porta M, López T, Pumarega J, Jariod M, Crous-Bou M, Marco E, et al. In pancreatic ductal adenocarcinoma blood concentrations of some organochlorine compounds and coffee intake are independently associated with KRAS mutations. Mutagenesis. 2009;24:513-21.
43. Gasull M, Porta M, Pumarega J, Vioque J, Bosch de Basea M, Puigdomènech E, et al. The relative influence of diet and serum concentrations of organochlorine compounds on K-ras mutations in exocrine pancreatic cancer. Chemosphere. 2010;79:686-97.
44. Crous-Bou M. Clinical and environmental influences on the prevalence of mutations in the K-ras oncogene in patients with pancreatic ductal adenocarcinoma. Doctoral dissertation [Dir.: Porta M], Universitat Autònoma de Barcelona, Barcelona, Spain; 2009. (http://www.imim.es/ programesrecerca/epidemiologia/en-documentsgrecm.html [accessed 23 Nov 2010].
45. Porta M, Pumarega J, López T, Jariod M, Marco E, Grimalt JO. Influence of tumor stage, symptoms and time of blood draw on serum concentrations of organochlorine compounds in exocrine pancreatic cancer. Cancer Causes Control. 2009;20:1893-906.
46. Porta M, Ferrer-Armengou O, Pumarega J, López T, Crous-Bou M, Alguacil A, et al. Exocrine pancreatic cancer clinical factors were related to timing of blood extraction and influenced serum concentrations of lipids. J Clin Epidemiol. 2008;61:695-704.
47. Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. 4th ed. Blackwell: Oxford; 2002.
48. Porta M, Pumarega J, Ferrer-Armengou O, López T, Alguacil J, Malats N, et al. Timing of blood extraction in epidemiologic and proteomic studies: results and proposals from the PANKRAS II Study. Eur J Epidemiol. 2007;22:577-88. (Pubitemid 47402434)
49. Gudjonsson B. Pancreatic cancer: survival, errors and evidence. Eur J Gastroenterol Hepatol. 2009;21:1379-82.